Preclinical studies with new pyrrolidine platinum(II) compounds

F. Sampedro, VWT W.T. Ruiz van Haperen, MA A. Izquierdo, M. Vicens, P. Santaló, M. Pueyo, M. Llagostera, E. Marcuello, L. De Andrés

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)


Four new platinum compounds containing different pyrrolidines as ligands are reported. In vitro tests show damage to bacterial DNA and participation of RecA protein in the repair system. In vitro tests using leukemia L1210 cells show growth inhibition by the new compounds within the range of cisplatin and carboplatin. In vivo tests using leukemia L1210 cells on male BDF1 show that these compounds are significantly active. © 1995 Elsevier, Paris.
Original languageEnglish
Pages (from-to)497-501
JournalEuropean Journal of Medicinal Chemistry
Issue number6
Publication statusPublished - 1 Jan 1995


  • antitumoral activity
  • cancer treatment
  • growth
  • inhibition
  • L1210 leukemia
  • platinum(II) compound
  • platinum(II)-DNA damage
  • pyrrolidine
  • viability


Dive into the research topics of 'Preclinical studies with new pyrrolidine platinum(II) compounds'. Together they form a unique fingerprint.

Cite this